Capital Flows Freely into Biotech Driven by Market Performance
Despite the continuing turbulence in the global capital markets investors have had no qualms about backing the biotech sector – more in public biotechs than in private ones, however. The average increase in the stock values of the 231 public biotech companies tracked by the BioWorld Stock Report is up 38 percent year-to-date.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter